New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
07:12 EDTMKGAYMerck KGaA CFO Matthias Zachert to step down
Matthias Zachert, Group CFO of Merck KGaA, Darmstadt, Germany, has informed the Chairman of the Family Board, Frank Stangenberg- Haverkamp, as well as the Chairman of the Merck KGaAExecutive Board, Karl-Ludwig Kley, that he has received the offer to be appointed as CEO of Lanxess AG, Cologne, Germany. He therefore asked for an early release of his duties. Merck will accept his request. The effective date will be announced in due course.
News For MKGAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 7, 2015
07:05 EDTMKGAYPfizer, Merck KGaA say avelumab gets FDA fast track designation
Subscribe for More Information
October 1, 2015
05:41 EDTMKGAYBioMarin to acquire rights to Phenylketonuria franchise from Merck Serono
Subscribe for More Information
September 28, 2015
07:02 EDTMKGAYSigma-Aldrich and Merck GaA 'making progress' toward completing acquisition
Sigma-Aldrich (SIAL) announced it is making progress toward closing the planned acquisition of the Company by Merck KGaA (MKGAY), Darmstadt, Germany. The closing is now expected within the next two months. On August 11, 2015, Sigma-Aldrich and Merck announced they had obtained all necessary antitrust approvals, with the approval of the European Commission (EC) being conditional upon the sale of parts of Sigma-Aldrich's solvents and inorganics business in Europe. Negotiations with potential buyers are in the final stage. Once a binding agreement has been signed, the EC must approve the buyer before Merck can complete the Sigma-Aldrich acquisition. On September 22, 2014, Merck and Sigma-Aldrich announced they had entered into a definitive agreement under which Merck, will acquire Sigma-Aldrich for $17 billion - $140 cash per share, establishing one of the leading players in the $130 billion global life science industry.
September 25, 2015
07:03 EDTMKGAYMerck KGaA, Pfizer announce FDA orphan drug designation for avelumab
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use